BRPI0512151A - solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol - Google Patents

solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol

Info

Publication number
BRPI0512151A
BRPI0512151A BRPI0512151-5A BRPI0512151A BRPI0512151A BR PI0512151 A BRPI0512151 A BR PI0512151A BR PI0512151 A BRPI0512151 A BR PI0512151A BR PI0512151 A BRPI0512151 A BR PI0512151A
Authority
BR
Brazil
Prior art keywords
tenatoprazole
sodium salt
monohydrate sodium
composition
monohydrate
Prior art date
Application number
BRPI0512151-5A
Other languages
English (en)
Inventor
Avraham Cohen
Francois Schutze
Suzy Charbit
Frederic Martinet
Herve Ficheux
Michel Homerin
Original Assignee
Sidem Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidem Pharma S A filed Critical Sidem Pharma S A
Publication of BRPI0512151A publication Critical patent/BRPI0512151A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

SOLUçãO CONCENTRADA DE SAL DE SóDIO MONOIDRATADO DO TENATOPRAZOL, COMPOSIçãO FARMACêUTICA, UTILIZAçãO DO SAL DE SóDIO MONOIDRATADO DO TENATOPRAZOL, PROCESSO DE PREPARAçãO DO SAL DE SóDIO MONOIDRATADO DO TENATOPRAZOL, E COMPOSIçãO PARA ADMINISTRAçãO POR VIA ORAL DO SAL DE SóDIO MONOIDRATADO DO TENATOPRAZOL A invenção refere-se ao sal de sódio monoidratado do tenatoprazol, representado pela fórmula: Aplicação em terapêutica pra o tratamento das patologias digestivas.
BRPI0512151-5A 2004-06-17 2005-06-17 solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol BRPI0512151A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406617A FR2871800B1 (fr) 2004-06-17 2004-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
PCT/FR2005/001528 WO2006005853A1 (fr) 2004-06-17 2005-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en tant qu'inhibiteur de la pompe a protons

Publications (1)

Publication Number Publication Date
BRPI0512151A true BRPI0512151A (pt) 2008-02-12

Family

ID=34948439

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512151-5A BRPI0512151A (pt) 2004-06-17 2005-06-17 solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol

Country Status (22)

Country Link
US (1) US7402593B2 (pt)
EP (1) EP1664044B1 (pt)
JP (1) JP5393028B2 (pt)
KR (1) KR101174932B1 (pt)
CN (1) CN101001858B (pt)
AT (1) ATE369366T1 (pt)
AU (1) AU2005261580C1 (pt)
BR (1) BRPI0512151A (pt)
CA (1) CA2568993C (pt)
CY (1) CY1106950T1 (pt)
DE (1) DE602005001918T2 (pt)
DK (1) DK1664044T3 (pt)
ES (1) ES2290921T3 (pt)
FR (1) FR2871800B1 (pt)
IL (1) IL179813A (pt)
MX (1) MXPA06014849A (pt)
NO (1) NO20070250L (pt)
NZ (1) NZ551866A (pt)
PL (1) PL1664044T3 (pt)
PT (1) PT1664044E (pt)
RU (1) RU2376304C2 (pt)
WO (1) WO2006005853A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2909380B1 (fr) * 2006-12-04 2009-02-20 Sidem Pharma Sa Sa Conglomerats de sels de potassium de tenatoprazole
CN102276602A (zh) * 2011-06-30 2011-12-14 福建省福抗药业股份有限公司 一种泰妥拉唑盐的精制方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH07157430A (ja) * 1993-10-12 1995-06-20 Tokyo Tanabe Co Ltd 安定化された医薬組成物
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH08239381A (ja) * 1995-03-02 1996-09-17 Toa Eiyoo Kk 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
AU2001276721A1 (en) * 2000-08-04 2002-02-18 Takeda Chemical Industries Ltd. Salts of benzimidazole compound and use thereof
CZ20032351A3 (cs) * 2001-02-02 2004-08-18 Tevaápharmaceuticaláindustriesáltd Způsob výroby substituovaných @@}@@pyridylmethylB sulfinyl @�H@benzimidazolů
CN1453278A (zh) * 2002-04-23 2003-11-05 中国人民解放军军事医学科学院放射医学研究所 一种拉唑类化合物及其制备方法与应用
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
DK1578742T3 (da) * 2002-12-06 2013-01-21 Nycomed Gmbh Fremgangsmåde til fremstilling af optisk rene aktive forbindelser
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CN100558726C (zh) * 2003-02-24 2009-11-11 田边三菱制药株式会社 泰妥拉唑的对映体及其在治疗中的应用
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2520157A1 (fr) * 2003-03-28 2004-10-14 Sidem Pharma Procede de preparation enantioselective de derives de sulfoxydes

Also Published As

Publication number Publication date
PT1664044E (pt) 2007-11-19
WO2006005853A1 (fr) 2006-01-19
JP5393028B2 (ja) 2014-01-22
AU2005261580C1 (en) 2011-06-16
RU2376304C2 (ru) 2009-12-20
ATE369366T1 (de) 2007-08-15
CA2568993C (fr) 2013-12-17
FR2871800B1 (fr) 2006-08-25
PL1664044T3 (pl) 2007-12-31
US7402593B2 (en) 2008-07-22
CY1106950T1 (el) 2012-09-26
IL179813A (en) 2011-01-31
ES2290921T3 (es) 2008-02-16
HK1106246A1 (en) 2008-03-07
DK1664044T3 (da) 2007-12-27
JP2008502665A (ja) 2008-01-31
FR2871800A1 (fr) 2005-12-23
CN101001858B (zh) 2012-03-14
KR20070045194A (ko) 2007-05-02
US20070179176A1 (en) 2007-08-02
MXPA06014849A (es) 2007-03-23
AU2005261580B2 (en) 2011-02-03
KR101174932B1 (ko) 2012-08-20
CA2568993A1 (fr) 2006-01-19
EP1664044A1 (fr) 2006-06-07
CN101001858A (zh) 2007-07-18
DE602005001918T2 (de) 2008-04-24
NO20070250L (no) 2007-03-14
AU2005261580A1 (en) 2006-01-19
DE602005001918D1 (de) 2007-09-20
RU2007101521A (ru) 2008-07-27
NZ551866A (en) 2010-07-30
IL179813A0 (en) 2007-05-15
EP1664044B1 (fr) 2007-08-08

Similar Documents

Publication Publication Date Title
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
ATE381535T1 (de) Phenethanolaminderivate
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
MX2009004908A (es) Compuestos quimicos.
TW200833663A (en) Therapeutic agents
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
ATE412647T1 (de) Substituierte n-arylpyrrolidine als selektive modulatoren des androgenrezeptors
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
ATE543492T1 (de) Behandlung von lungenkrebs
EP4578461A3 (en) Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa
BRPI0514735B8 (pt) derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
BRPI0517259A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.